NASDAQ: ELTX - Elicio Therapeutics, Inc.

半年間の収益性: +54.87%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Elicio Therapeutics, Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers.

さらに詳しく
It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2021-02-05
ISIN US28657F1030
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://elicio.com
Цена ао 8
1日あたりの価格変動: +1.56% (7.67)
週ごとの価格変動: -10.97% (8.75)
月ごとの料金変更: -6.26% (8.31)
3ヶ月間の価格変動: +51.26% (5.15)
半年間の価格変動: +54.87% (5.03)
年間の価格変動: +2.5% (7.6)
3年間の価格推移: +240.17% (2.29)
年初からの価格変動: +55.8% (5)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 0 0
P/BV 3.16 5
P/E 0 0
EV/EBITDA -0.8654 0
合計: 3.13

効率

名前 意味 学年
ROA, % -129.65 0
ROE, % -309.46 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.2001 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % 875.86 10
収益性 Ebitda, % 170.21 10
収益性 EPS, % 364.05 10
合計: 10
さらに詳しく

機関 音量 共有, %
Vanguard Group Inc 174894 1.71
CM Management, LLC 50000 0.49
Geode Capital Management, LLC 44344 0.43
Renaissance Technologies, LLC 16466 0.16
Citadel Advisors Llc 14005 0.14
Meyer Handelman Co 13899 0.14
Bridgeway Capital Management, Inc. 12500 0.12
Tower Research Capital LLC (TRC) 2045 0.02
Steward Partners Investment Advisory, LLC 1554 0.02
Bank of America Corporation 1149 0.01

ETF共有, %年間の利益率, %配当金, %
iShares Micro-Cap ETF 0.00961 17.09 1.54048
0.0117.091.54



スーパーバイザー 役職 支払い 生年
Mr. Robert T. Connelly CEO, President & Director 612k 1960 (65 年)
Dr. Christopher M. Haqq M.D., Ph.D. Executive VP, Head of Research & Development and Chief Medical Officer 589k 1966 (59 年)
Prof. Darrell J. Irvine Ph.D. Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board N/A
Mr. Michael DiVecchia Senior Vice President of Operations & Human Resources N/A
Dr. Peter DeMuth Ph.D. Chief Scientific Officer N/A 1986 (39 年)
Ms. Esther Welkowsky Senior Vice President of Clinical Development N/A
Ms. Joy Seymour VP & Head of Regulatory Affairs N/A
Ms. Megan C. Filoon General Counsel, Secretary & Compliance Officer N/A
Dr. Thian Kheoh Ph.D. Senior Vice President of Biometrics N/A

住所: United States, Boston. MA, 451 D Street - Googleマップで開く, Yandexマップを開く
Webサイト: https://elicio.com